Boundless Bio, Inc.
Formerly Pretzel Therapeutics, Inc.
Boundless Bio, Inc. is listed today as Boundless Bio, Inc.: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2023 | $100 M | No. 3 | $50 to $250 million | equity | SEC | |
| Apr 2021 | $106 M | No. 2 | $50 to $250 million | equity | SEC | |
| Aug 2018 | $23 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Boundless Bio, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2023).
SEC Form D · Aug 2023
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2023
That is all the official record says: Boundless Bio, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Boundless Bio, Inc. are on record.
Investors#
12 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| ARCH Venture Fund IX Overage, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| ARCH Venture Fund X Overage, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| ARCH Venture Partners IX, LLC | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| ARCH Venture Partners IX, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| ARCH Venture Partners IX Overage, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| ARCH Venture Partners X, LLC | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| ARCH Venture Partners X Overage, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| RA Capital Healthcare Fund LP | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Ra Capital Management, L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| RA Capital Nexus Fund II, L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 28 investors.
Largest shareholders today
Institutions holding Boundless Bio, Inc. shares, as of Sep 30, 2026.
- Tang Capital Management LLC$7 M12.03%
- ARCH Venture Management, LLC$7 M11.41%
- FMR LLC$6 M10.86%
- ADAR1 Capital Management, LLC$5 M8.02%
- Cormorant Asset Management, LP$2 M3.98%
- Vanguard Capital Management LLC$1 M2.53%
- Wellington Management Group LLP$1 M2.36%
- Renaissance Technologies LLC$1 M2.09%
- Two Sigma Investments, LP$1 M1.59%
- Acadian Asset Management LLC$1 M1.47%
- Alyeska Investment Group, L.P.$1 M1.27%
- China Universal Asset Management Co., Ltd.$1 M0.99%
- Superstring Capital Management LP$1 M0.87%
- RBF Capital, LLC$1 M0.85%
- Citadel Advisors LLC$0 M0.67%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Zachary D. Hornby | Executive officer | Aug 2023 |
| Benjamin D. Cravatt, Ph.D. | Director | Aug 2023 |
| Christine D. Brennan, Ph.D. | Director | Aug 2023 |
| Fabio D. Pucci, Ph.D. | Director | Aug 2023 |
| Jakob D. Loven, Ph.D. | Director | Aug 2023 |
| Jennifer D. Lew | Director | Aug 2023 |
| Jonathan D. Lim, M.D. | Director | Aug 2023 |
| Kristina D. Burow | Director | Aug 2023 |
| Zachary D. Hornby | Director | Aug 2023 |
| Benjamin Sung Cravatt, Ph.D. | Director | May 2021 |
| Carolyn D. Ng, Ph.D. | Director | May 2021 |
| Ho Sung Cho, Ph.D. | Director | May 2021 |
| Jonathan E. Lim, M.D. | Director | May 2021 |
| Kristina E. Burow | Director | May 2021 |
| Chris D. Hassig, Ph.D. | Director | Mar 2020 |
| Jason D. Christiansen, Ph.D. | Director | Mar 2020 |
| Scott D. Moorefield, Ph.D. | Director | Mar 2020 |
About
Company in San Diego, United States.
Went public since 2024. Its SEC number is that of a company listed on a stock exchange.